Hi {{lead.First Name:default=edit me}},

You know that human biospecimens represent the best research model, but accessing the right human samples can be challenging. Fortunately, Takeda's pipeline matches well with Sanguine’s network of highly characterized, recallable patient donors, so you can choose I/E criteria and timely receive the right samples, including PBMCs and leukopaks. Search Sanguine's  nationwide donor network, which includes:

  • >13,000 donors with autoimmune indications, our most diverse patient group
  • >2,000 donors with metabolic diseases, including diabetes (type I & II) and CKD
  • >1,500 donors with neurological disorders, including Alzheimer’s and Parkinson’s

Takeda’s commitment to treating inflammatory conditions and Sanguine’s goal of connecting patients to researchers explains why our companies have partnered on 40 studies. Let’s discuss whether we can continue succeeding for patients.

Warm Regards,


Samrina Lamichhane
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com